Annual Allogeneic Cell Therapies Summit on May 22-25, 2023 in Boston, United States

The entire cell therapy field is experiencing a shift towards allogeneic platforms as the blockbuster potential to achieve a truly off-the-shelf, universal, and efficacious cell therapy offers great advantages such as reduced cost, production and patient accessibility compared to its autologous counterparts.

Placing a spotlight on what has been deemed the 'future of cell therapy', the 5th Allogeneic Cell Therapies Summit returns to Boston this May as the leading industry focused meeting dedicated to accelerating the safety, durability and clinical translation of off-the-shelf therapies to deliver affordable and accessible treatments for patients in critical need.

Across a jam-packed agenda consisting of 4 tracks, 6 Workshops, a NEW Focus Day, and 60+ hours of content, 50+ speakers will lead you and 300+ of your peers in discussions that will help to transform universal cell therapy for patients across the globe.

URLs:

Tickets: https://go.evvnt.com/1543821-2?pid=10008

Brochure: https://go.evvnt.com/1543821-3?pid=10008

Prices:
Drug Developer - Full Access Pass (Conference + Pre-Conference Workshop Day + Post-Conference Focus Day): USD 5595.00,
Drug Developer - Conference + Pre-Conference Workshop Day: USD 4297.00,
Drug Developer - Conference + Post-Conference Focus Day: USD 4297.00,
Drug Developer - Conference Only: USD 2999.00,
Small Biotech - Full Access Pass (Conference + Pre-Conference Workshop Day + Post-Conference Focus Day): USD 4795.00,
Small Biotech - Conference + Pre-Conference Workshop Day: USD 3697.00,
Small Biotech - Conference + Post-Conference Focus Day: USD 3697.00,
Small Biotech - Conference + Conference Only: USD 2599.00,
Service Provider - Full Access Pass (Conference + Pre-Conference Workshop Day + Post-Conference Focus Day): USD 6795.00,
Service Provider - Conference + Pre-Conference Workshop Day: USD 5297.00

Speakers: Albert Ribickas, Associate Director, Operations, Cell Therapy Facility, Moffitt Cancer Center, Amnon Eylath, VP, Head of Quality, Minovia Therapeutics, Amol Thote, Senior Director, Bayer, Austin Bigley, VP, R and D, Indapta Therapeutics, Barbra Sasu, CSO, Allogene, Beatriz Aranda, Orgilles Team Leader, Cellectis, Bertie MacArthur, Account Manager, Beacon Targeted Therapies, Blake Aftab, CSO, Adicet Bio Inc., Cédric Cleyrat, Scientific Director Cell Therapy Engineering Strategy and Innovation, Bristol Myers Squibb, Charles Nicolette, CEO, CoImmune, Cokey Nguyen, CSO, Atara Biotherapeutics, Colleen Delaney, Scientific Founder, EVP of R and D, Deverra Therapeutics, Derek Tan, Member, Tri-institutional Professor, Chair, Chemical Biology Program, Memorial Sloan Kettering Cancer Center, Donna Rill, CTO, Triumvira Immunlolgics, Ebba Sohlberg, Project Manager, Karolinska Institutet, Elisa Gambini, CTO-COO, Oloker Therapeutics, Elizabeth Garner, Director - T Cell Therapeutics, Caribou Biosciences, Erika Von, Euw President, Deverra Therapeutics, Evren Alici, Associate Professor, Co-Director, NextGenNK Competence Center, Karolinska Institutet, Guanghui Hu, CEO, Naki Therapeutics, Hina Chaudhry, Professor of Medicine, Icahn School of Medicine at Mount Sinai, Jason Acker, Associate VP, Professor, Laboratory Medicine and Pathology, University of Alberta, Jeff Liter, President, CEO, Luminary Therapeutics, Jim Green, Senior Director, Engineering and Automation, Bayer, Joseph Gold, VP, Technical Operations, Catamaran Bio, Joy Zhou, VP, Mink Therapeutics, Kate Rochlin, COO, IN8Bio, Ken Chrobak, SVP of CMC, Wugen, Luis Borges, CSO, Century Tx, Luke Pase, CTO, Anocca, Marco Alessandrini, CTO, Antion Biosciences, Mark Frattini, CMO, Cellectis, Mark Throsby, COO/CSO,Gadeta, Michael Baker, CEO, Arovella Therapeutics, Noelle Hutchins, Associate, Omega Funds, Omid Veiseh, Co-Founder and Chief Scientific Advisor ,Avenge Bio, Oscar Segurado, CMO, ASC Therapeutics, Renier J. Brentjens, Deputy Director, Roswell Park Comprehensive Cancer Center, Richard Lopez, CEO, PhosphoGam, Rick Morgan, CSO, Be Biopharma, Sai-Wen Tang, R and D Director, Acepodia, Samuel Zhang, CBO, Gracellbio Biotechnologies, Stephen Chen, CTO, Tevogen Bio, Sumona Sarkar, Biomedical Engineer, NIST, Tirtha Chakraborty, CSO, Vor Biopharma, Tracey Turner, Scientist, Formulation and Cryobiology in the Cell Therapy Development Organization, Bristol Myers Squibb, Uday Kumar, K VP– Technical Operation, Stempeutics Research Pvt Ltd, Veronica Ricci, QA and RA, Oloker Therapeutics, William Van Der Touw, Senior VP Translational Research, Celularity Inc., Yu Qian, Associate Director, Oncology Cell Therapy Technology and Product Engine, Takeda

Time: 09:00 to 15:30